Founded in 2024 as a spin-off from the Institut Langevin (CNRS), Owlo focuses on non-invasive, 3D, real-time cellular imaging for IVF. Its core product is an innovative microscope module paired with software and AI that enhances the selection of oocytes and embryos, aiming to increase IVF success rates. The technology translates academic research into a clinical tool designed for embryologists. Owlo plans to secure CE certification and begin clinical deployment by 2026. The company recently secured €1.5 million in funding to advance product development and regulatory work. No revenue or user numbers have been disclosed, underscoring its early-stage, pre-commercial status.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025